Immunomedics Reports Promising Activity With Veltuzumab In Relapsed Immune Thrombocytopenia

-- Subcutaneous Injections of Low-Dose Veltuzumab Produced High Objective Response Rate as a Single Agent --

-- Final Results From Phase I/II Study Presented at the 55 th Annual Meeting of the American Society of Hematology --

NEW ORLEANS, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that veltuzumab, administered subcutaneously as a single agent, produced an overall objective response rate of 49% in 47 evaluable patients with relapsed immune thrombocytopenia (ITP), including 15 patients (32%) who reported a complete response.

For the 23 patients who responded, median time to relapse from initial veltuzumab dose was 9.2 months, with 11 patients (48%) maintaining their response for more than 1 year. Veltuzumab showed activity across all dose levels tested, including the lowest dose of 80 mg x 2, and was active in patients with limited disease duration of 1 year or less, as well as in more heavily pretreated patients with chronic refractory disease.

It is of interest to note that 9 patients with the chronic disease had previously received thrombopoietin receptor (TPO-R) agonists, such as eltrombopag and romiplostim, which are the newest approved drugs for patients with chronic ITP who are refractory to other treatments. Out of these 9 patients, 2 had a complete response, one lasted for more than 1 year while the other is still ongoing at 4.6 months.

"We are very pleased with these promising results. The fact that some patients relapsed to TPO-R agonists responded to veltuzumab is particularly encouraging," commented Cynthia L. Sullivan, President and Chief Executive Officer. "We are currently evaluating various options for further clinical development of veltuzumab in this and other autoimmune disease indications, as well as in oncology, including licensing arrangements and collaborations with outside study groups," Ms. Sullivan added.

If you liked this article you might like

Kite Takeover by Gilead Lifts Biotech Stocks

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Seattle Genetics Scrap License Deal

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Bullish and Bearish Reversals for This Week